DHDaniel B. Hawcutt

Daniel B. Hawcutt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel B. Hawcutt has a total of 411 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

    by Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju

    Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to contribute substantially to preventable morbidity and mortality. Long‐acting therapeutics (LATs) may help address selected pediatric health priorities by sustaining therapeutic or prophylactic exposure, reducing dosing frequency, and improving adherence and implementation feasibility. This review synthesizes insights from the pediatric health session of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health workshop. The session considered priority pediatric conditions in which existing or emerging LAT approaches could have clinical or public health impact, including lower respiratory tract infections, malaria, tuberculosis, HIV, and syphilis, as well as selected noninfectious indications such as childhood cancer and growth hormone deficiency. We then examine clinical pharmacology and safety considerations central to pediatric LAT development, including developmental pharmacokinetics, absorption‐limited disposition and flip‐flop kinetics, pharmacokinetic tailing, dose selection, model‐informed development, and injection‐site tolerability. The review also discusses long‐acting technology platforms with potential pediatric applications, route‐of‐administration considerations, excipient safety, formulation design, acceptability, and implementation challenges. Finally, we propose recommendations to support pediatric LAT development, including early integration of developmental pharmacology, age‐ and weight‐informed dosing, standardized acceptability assessment, product‐attribute frameworks, regulatory engagement, and equitable access planning. Realizing the potential of LATs for children will require coordinated, child‐centered, and equity‐driven approaches that address evidence generation, formulation suitability, implementation context, and affordability from the outset.

  • Open Access

    Expanding the Developmental Origins of Health and Disease beyond maternal behaviors

    by Alice Rhiannon Lee, Daniel B. Hawcutt, Jennifer K. Quint, Ian P. Sinha

    Developmental Origins of Health and Disease (DOHaD) research has long emphasized maternal pregnancy behaviors as key determinants of child health. New evidence recently published in PLOS Medicine suggests the greatest opportunities to improve child health may lie in tackling socioeconomic disadvantage rather than maternal behavior alone.


  • CHATD Questionnaire: Development, Validation and Evaluation of Child and Parent Attitudes Towards Deprescribing

    by James Moss, Asia N. Rashed, Elena Rybka, Stephen Tomlin, Emily Reeve, Paul Christiansen, Lauren Walker, Daniel B. Hawcutt

    Aims: Polypharmacy exists in children and young people (CYP), generating clinician concern and a desire to deprescribe. This study validated and applied a questionnaire to assess the attitudes of CYP and their parents/guardians towards polypharmacy and deprescribing. Methods: A paediatric version of the Revised Patient Attitudes Towards Deprescribing (rPATD) was developed—the Child and Parent Attitudes Towards Deprescribing (CHATD) questionnaire. Validation included: Content evaluation, face validity, factor analysis, internal reliability and test re‐test reliability. Participants were prospectively recruited from three UK paediatric hospitals. The questionnaire comprised two global questions and four factors concerning participants medications: burden, appropriateness, concerns about stopping and involvement. Responses were recorded on a 5‐point Likert scale (1 = strongly disagree to 5 = strongly agree ; appropriateness reverse scored). Results: A total of 216 responses were analysed (149 parents, 67 CYP). Factor analysis supported the four‐factor structure, with good internal reliability (McDonald's ω t ≥ 0.7) and test–retest reliability (all ICCs >0.75). Compared with parents, CYP reported greater medication burden (3.0 vs. 2.4, p = .003), lower perceived appropriateness (3.6 vs. 4.2, p = .008) and less involvement (3.8 vs. 4.8, p < .001). Most parents (70%) and 55% of CYPs were happy to have a medication deprescribed if the doctor agreed. Among CYP, higher appropriateness scores were associated with greater satisfaction with current medications (OR 9.34, 95% CI 3.39–25.77) and lower willingness to stop a medicine (OR 0.21, 95% CI 0.09–0.48). Conclusions: CHATD is a valid, reliable tool for assessing deprescribing attitudes among CYP and parents. Most respondents were willing to consider deprescribing under medical guidance.

  • Open Access

    Validating exacerbations of asthma in electronic health records: a systematic review

    by Elizabeth Moore, Zakariah Gassasse, Ian Sinha, Daniel B. Hawcutt, Jennifer K. Quint

    Background: Previous studies have shown that the algorithms and code lists used to define asthma exacerbations vary across different sources of data, if reported at all. Defining and validating asthma exacerbations in electronic health records (EHR) would help to improve future research on asthma using EHR by leading to more consistent and comparable evidence. Methods: We systematically reviewed the literature to evaluate studies that define exacerbations of asthma in EHR and report which algorithms have the highest validity. An adapted version of the QUADAS-2 designed for this review was used to assess risk of bias. Results: Of the studies yielded by the search, only five met the inclusion criteria. Eligible studies used algorithms that contained codes from versions or modifications of either the 9th or 10th revisions of the International Statistical Classification of Diseases and Related Health (ICD-9 or ICD-10), and validity scores varied. Using the ICD-9 code 493 within algorithms to detect asthma exacerbations, sensitivity scores varied from 44.8% to 91.28% and specificity was >85%. Using the ICD-9 code 493.xx as the principal and secondary diagnosis in claims data, validity measures were all >85%. Using the ICD-10 code J45, scores for sensitivity, specificity and negative predictive value were also all >85%. Conclusions: Algorithms have been used to identify asthma exacerbations in EHR with varying degrees of validity. Algorithms including the ICD-9 code 493.xx or the ICD-10 code J45 to detect asthma exacerbations had high validity scores. However, there was a risk of bias in these studies and urgent work is needed using robust methods to validate definitions for future research using EHR.


  • Open Access

    “We’ve managed to find our own path of how we do it”: exploring parental perceptions of using age-inappropriate formulations at home—a qualitative study

    by Jennifer C. Duncan, Louise E. Bracken, Daniel B. Hawcutt, Matthew Peak, Mark A. Turner

    Introduction: The administration of medicines to children poses distinct challenges, largely due to the limited availability of authorised, commercially available, age-appropriate formulations (AaFs). In the absence of suitable options, parents and carers are often required to manipulate age-inappropriate formulations (AiFs) to facilitate administration. However, little is known about their perceptions and experiences when administering AiFs to children at home. Methods: Qualitative exploratory study. Participants were recruited from a UK paediatric hospital. Semi-structured interviews were conducted either in participants’ homes or at the hospital. Interviews were audio-recorded, transcribed verbatim, and thematically analysed using NVivo v10. Topics explored included formulation types, dosage form manipulation, medicine supply, and administration practices. Results: Over sixty outpatient clinics were screened; 34 families expressed interest, and 13 completed interviews between September 2016 to February 2017 (mean duration: 35 min). Eleven interviews were conducted at home and two in hospital; 12 participants were mothers, and 8 of the 13 children discussed were female. Thematic analysis identified five key themes: (1) inappropriate formulations; (2) unlicensed medicine and off-label prescribing; (3) framework of appropriateness; (4) knowledge, training, communication, and relationships; and (5) patient and family experience. Parents often relied on prescriber instructions without fully understanding the implications of manipulating medicines, indicating a gap in support and knowledge transfer. Discussion: These findings highlight the emotional and practical burdens families face when administering age-inappropriate medicines, including the time and effort required to ensure accurate dosing and safe administration. The study emphasises the need for increased access to child-appropriate formulations of essential medicines and more child-centred prescribing practices. Where legacy medicines remain the only option, healthcare professionals can support children to safely swallow solid oral dosage forms, such as tablets, and educate families on safe medicine manipulation. Further research is needed to better understand the magnitude of these burdens and guide future paediatric formulation development.


  • Installing Air Purifiers in the Homes of Children With Severe Asthma: Outcomes and Family Perspectives From a Feasibility Study

    by Karl A. Holden, Daniel B. Hawcutt, Ian P. Sinha

    Background: Poor indoor air quality (IAQ) contributes to asthma morbidity, particularly affecting children and young people (CYP) from socioeconomically deprived backgrounds. Air purification devices may improve IAQ and asthma symptoms, but real‐world evidence remains limited. Aim: To assess the feasibility, acceptability, and potential clinical impact of installing an air purifier in the homes of CYP with severe asthma. Methods: An unblinded feasibility study recruiting children ≤ 15 years with a confirmed diagnosis of asthma attending a regional severe asthma service. Participants selected by computer‐generated random allocation. An air purifier (manufactured by Rensair Ltd.) was installed in each home, with instructions to operate continuously on “quiet mode” for 1‐year, and operating costs covered. Data on asthma management and symptoms, quality of life, and qualitative feedback were collected and analysed using thematic analysis. Results: Twenty CYP were recruited (mean age: 11.2 (SD: 2.68), 60% boys). Thematic analysis of feedback from CYP and families indicated high acceptability and perceived improvements in night‐time symptoms and IAQ. Over this 12‐month study period, the mean annual number of systemic corticosteroid courses decreased from 4.2 to 2.15 ( p = 0.006) from the previous year, and unscheduled primary care visits fell from 4.0 to 1.8 ( p = 0.02). Trends towards marginal improvements in asthma control test mean scores (13.3 to.14.2 for < 12 years ( p = 0.2), 15.5 to 16.8 for ≥12 years ( p = 0.6) and quality of life scores were observed (54.6 to 62.4 for total score ( p = 0.08), 17.2 to 19.8 for emotional domain ( p = 0.07) and 13.6 to 13.9 for activity domain ( p = 0.7)), with a statistically significant increase in the symptom domain of the Mini‐PAQLQ (23.8 to 28.8 p = 0.04). Conclusions: Air purifiers may offer a feasible, acceptable, and potentially beneficial intervention for children with severe asthma, particularly in settings with poor IAQ. Larger controlled trials are warranted to confirm these findings and inform implementation. Trial Registration: NCT05817357.


  • Open Access

    Developing medication independence: The experience of UK teenagers

    by Holly Hutchins, Charlotte King, Louis Bioletti, Tsegay Gebru, Daniel B. Hawcutt

    Aims: There is a progression through childhood from being provided medications by caregivers to having to take responsibility for medications yourself, but little is known about when the transition of adolescents managing medicines begins. The aim of this study was to obtain a cross‐sectional sample of UK adolescents and when they become independent with medications. Methods: A prospective anonymous survey was conducted during the school academic year 2023/2024. Participating secondary schools were members of the Alder Hey Research Ambassador Scheme. This survey included questions to assess their demographics and usage of medications. Results: A total of 3164 responses were received from 18 schools and colleges. Among participants, 1749 (55.4%) were female, with a mean age of 15.3 years (range 13–18). In the last 6 months, 1414 (45%) participants had used prescription medications, and 1660 (53%) had used over‐the‐counter (OTC) medications. Overall, 937 (30%) participants reported using medications without parental knowledge, of which 67 (7.2%) were prescription medicines. Female adolescents were more likely than male adolescents for all ages to be using medicines without parental knowledge ( p < 0.001). OTC medicines purchased were most commonly reported as analgesics (paracetamol and ibuprofen) and antihistamines. Conclusions: Young people acquire different aspects of medication independence throughout the teenage years and are varied among females and males. These data can inform the timing and content of educational information supplied to adolescents regarding medications and can be utilized by educational institutes in the United Kingdom, as well as healthcare and pharmaceutical industries to ensure their information is appropriate for different ages.

  • Open Access

    CHATD Questionnaire: Development, Validation and Evaluation of Child and Parent Attitudes Towards Deprescribing

    by James Moss, Asia N Rashed, Elena Rybka, Stephen Tomlin, Emily Reeve, Paul Christiansen, Lauren Walker, Daniel Hawcutt

    Aim Polypharmacy exists in children and young people (CYP), generates clinician concern and a desire to undertake deprescribing, tempered by concerns about parental acceptability. The aim of this study was to validate and apply a questionnaire to assess the attitudes of CYP and their parents/guardians towards polypharmacy and deprescribing. Methods A paediatric version of the Revised Patient Attitudes Towards Deprescribing (rPATD) was developed – the Child and Parent Attitudes Towards Deprescribing (CHATD) questionnaire. Validation steps included: Content evaluation panel, face validity (piloting), factor analysis, internal reliability and test re-test reliability. Participants were prospectively recruited from three UK paediatric hospitals. The questionnaire includes two global questions and four factors concerning participants medications: burden, appropriateness, concerns about stopping, and involvement. Results 216 participant responses were analysed (149 parents, 67 CYP). Factor analysis showed the CHATD questionnaire aligned well with the underlying structure of the rPATD with good internal reliability and test-retest reliability. In comparison to their parents, CYP felt their medications were more burdensome (3.0 vs 2.4, p=0.003), less appropriate (3.6 vs 4.2 p=0.008) and wanted and experienced less involvement (3.8 vs 4.8 p<0.001). Most parents (70%) and 55% of CYPs were happy to have a medication deprescribed if the doctor agreed. Conclusions The CHATD questionnaire is a valid, reliable tool for assessing deprescribing attitudes among children, young people, and parents. Whilst CYP and their parents showed some concern over the stopping of their medications, most parents and CYP were willing to have a medication deprescribed under the guidance of their doctor.

  • Open Access

    Prescriptions of corticosteroids in primary care and related clinical indications: a national population-based cohort study in England

    by Hannah Whittaker, Meghna Jani, Fiona A Pearce, Samira Bell, Constantinos Kallis, Dan Hawcutt, Sara Brown, Ana Luisa Neves, Jo Robson, Ting Shi, et al.